FindTrial
Sign In

The application of Tegilerdine Fumarate Injection in outpatient hysteroscopic surgery

Study on the application of Tegilerdine Fumarate Injection in outpatient hysteroscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106850
Enrollment
Unknown
Registered
2025-07-30
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopic surgery

Interventions

Group S:Sufentanil
Group T:Tegilerdine Fumarate Injection

Sponsors

The First Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65 years, ASA grade I-II, BMI 18-28kg/m^2, no respiratory disease before surgery and normal airway assessment, and planned to undergo hysteroscopic surgery under non-endotracheal intubation general anesthesia.

Exclusion criteria

Exclusion criteria: A. Allergy to experimental drugs B. Combined with severe cardiac, pulmonary, hepatic, renal, neurological and psychiatric diseases C. Long-term use of opioids, analgesics, sedative drugs, or a history of alcoholism D. Suffering from sleep apnea syndrome E. Chronic pelvic pain before surgery

Design outcomes

Primary

MeasureTime frame
Incidence of hypoxemia;—

Secondary

MeasureTime frame
Number of airway interventions;Time of disappearance of consciousness;Propofol dosage;NRS;—

Countries

China

Contacts

Public ContactZhuang Shaohui

The First Affiliated Hospital of Shantou University Medical College

doctorzsh@163.com+86 135 0295 0710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026